KLRA vs RYTM
KLRA: A clinical-stage biotech developing a diversified pipeline of GLP-1-based obesity management drugs, led by a dual GLP-1/GIP agonist injectable designed to deliver superior weight loss potential. RYTM: Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related neuroendocrine diseases.
Side-by-side fundamentals
| Metric | KLRA | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.79 | $103.97 | |
| Market cap as of 2026-07-23 | $2.4B | $7.1B | |
| PEG as of 2026-07-23 | n/a | -2.97 | |
| Net margin as of 2026-07-23 | n/a | -93.3% | |
| Gross margin as of 2026-07-23 | n/a | +89.4% | |
| Operating margin as of 2026-07-23 | n/a | -90.9% | |
| ROE as of 2026-07-23 | -23.4% | -86.5% | KLRA higher |
| ROA as of 2026-07-23 | -21.5% | -45.0% | KLRA higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.46 | KLRA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +58.7% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +100.2% | |
| Beta as of 2026-07-23 | 1.68 | 1.97 | |
| 1-year return as of 2026-07-22 close | -29.2% | +18.4% | RYTM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.